In this study, we aimed to explore the association of DMTs for MS and FDA-approved BTK inhibitors (for indications other than MS) with the occurrence of epilepsy using reports from the US Food and Drug Administration Adverse Event Reporting System (FAERS). The gene discussed is BTK; the disease is epilepsy.